Cayuga Biotech Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 9

Employees

  • Latest Deal Type
  • Seed

  • Latest Deal Amount
  • $5M

  • Investors
  • 16

Cayuga Biotech General Information

Description

Developer of a clinical-stage biopharmaceutical company designed to address life-threatening hemorrhage by harnessing the body's innate ability to stop bleeding. The company offers a pipeline of therapies, including a polyP-SNP complex for acute major hemorrhage, programs for inherited bleeding disorders, and early-stage healing initiatives, enabling patients with serious bleeding conditions to achieve improved recovery and survival outcomes.

Contact Information

Website
www.cayugabiotech.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 500 Eighth Avenue, Front 3
  • Suite 1596
  • New York, NY 10018
  • United States
+1 (908)
Primary Industry
Biotechnology
Vertical(s)
Nanotechnology, Life Sciences
Corporate Office
  • 500 Eighth Avenue, Front 3
  • Suite 1596
  • New York, NY 10018
  • United States
+1 (908)

Cayuga Biotech Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cayuga Biotech Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Seed Round 11-Dec-2025 $5M Completed Clinical Trials - Phase 1
9. Grant 11-Dec-2025 Completed Clinical Trials - Phase 1
8. Seed Round 28-Mar-2024 Completed Pre-Clinical Trials
7. Seed Round 11-Mar-2023 Completed Pre-Clinical Trials
6. Accelerator/Incubator 01-Jan-2023 Completed Pre-Clinical Trials
5. Grant 30-Jun-2022 Completed Pre-Clinical Trials
4. Grant 31-Dec-2021 Completed Pre-Clinical Trials
3. Accelerator/Incubator 21-May-2020 Completed Pre-Clinical Trials
2. Grant 14-Aug-2017 $483K Completed Startup
1. Accelerator/Incubator Completed Startup
To view Cayuga Biotech’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Cayuga Biotech Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a clinical-stage biopharmaceutical company designed to address life-threatening hemorrhage by harnessing th
Biotechnology
New York, NY
9 As of 2026

Leiden, Netherlands
 

Berkeley, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Cayuga Biotech Competitors (3)

One of Cayuga Biotech’s 3 competitors is VarmX, a Formerly VC-backed company based in Leiden, Netherlands.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
VarmX Formerly VC-backed Leiden, Netherlands
Coagulant Therapeutics Venture Capital-Backed Berkeley, CA
CellPhire Therapeutics Venture Capital-Backed Rockville, MD
You’re viewing 3 of 3 competitors. Get the full list »

Cayuga Biotech Patents

  • 1

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 1

    Pending

  • Expiring in next 12 mo

Cayuga Biotech Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025265036-A1 Polyphosphate-functionalized nanoparticles and methods of use Pending 21-Jun-2024

Cayuga Biotech Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cayuga Biotech Investors (16)

Investor Name Investor Type Holding Investor Since Participating Rounds
Gopher Angels Angel Group Minority
Mass Medical Angels Angel Group Minority
Medical Technology Enterprise Consortium Government
SideCar Angels Angel Group Minority
Symbiotic Ventures Venture Capital Minority
You’re viewing 5 of 16 investors. Get the full list »

Ready to get started?

Request a free trial

Cayuga Biotech FAQs

  • When was Cayuga Biotech founded?

    Cayuga Biotech was founded in 2015.

  • Where is Cayuga Biotech headquartered?

    Cayuga Biotech is headquartered in New York, NY.

  • What is the size of Cayuga Biotech?

    Cayuga Biotech has 9 total employees.

  • What industry is Cayuga Biotech in?

    Cayuga Biotech’s primary industry is Biotechnology.

  • Is Cayuga Biotech a private or public company?

    Cayuga Biotech is a Private company.

  • What is Cayuga Biotech’s current revenue?

    The current revenue for Cayuga Biotech is .

  • How much funding has Cayuga Biotech raised over time?

    Cayuga Biotech has raised $7.2M.

  • Who are Cayuga Biotech’s investors?

    Gopher Angels, Mass Medical Angels, Medical Technology Enterprise Consortium, SideCar Angels, and Symbiotic Ventures are 5 of 16 investors who have invested in Cayuga Biotech.

  • Who are Cayuga Biotech’s competitors?

    VarmX, Coagulant Therapeutics, and CellPhire Therapeutics are competitors of Cayuga Biotech.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process